Enhancing Irbesartan Bioavailability via Solid Dispersion : Optimizing Dissolution of Irbesartan Through Advanced Solid Dispersion Techniques

Rashmitha Vallala

ISBN 10: 6208119715 / ISBN 13: 9786208119713

Published by LAP LAMBERT Academic Publishing, 2024

About this Item

nach der Bestellung gedruckt Neuware - Printed after ordering - Hypertension is a prevalent condition, especially in those over 50, and can lead to severe cardiovascular complications. Irbesartan, an angiotensin II receptor blocker (ARB), is commonly used to manage hypertension, but its low aqueous solubility (1 ¿g/ml) limits its bioavailability. This study aimed to improve Irbesartan¿s solubility through solid dispersions using carriers like ¿-cyclodextrin, HPMC K4M, PEG4000, and Gelatin. ¿-cyclodextrin showed the greatest enhancement in solubility, as confirmed by phase solubility studies. Characterization through DSC and SEM indicated the drug¿s transformation from crystalline to amorphous form, improving dissolution. FTIR studies confirmed no interaction between the drug and carriers. In vitro dissolution tests revealed that ¿-cyclodextrin (1:9) formulations significantly increased the dissolution rate compared to pure Irbesartan and other carriers. Thus, using ¿-cyclodextrin in solid dispersions effectively enhances Irbesartan¿s solubility and therapeutic potential in treating hypertension.

Seller Inventory # 9786208119713

Bibliographic Details

• Title: Enhancing Irbesartan Bioavailability via Solid Dispersion : Optimizing Dissolution of Irbesartan Through Advanced Solid Dispersion Techniques
• Publisher: LAP LAMBERT Academic Publishing
• Publication Date: 2024
• Language: English
• ISBN 10: 6208119715
• ISBN 13: 9786208119713
• Binding: Taschenbuch
• Condition: Neu

About this title

Synopsis

Hypertension is a prevalent condition, especially in those over 50, and can lead to severe cardiovascular complications. Irbesartan, an angiotensin II receptor blocker (ARB), is commonly used to manage hypertension, but its low aqueous solubility (1 μg/ml) limits its bioavailability. This study aimed to improve Irbesartan’s solubility through solid dispersions using carriers like β-cyclodextrin, HPMC K4M, PEG4000, and Gelatin. β-cyclodextrin showed the greatest enhancement in solubility, as confirmed by phase solubility studies. Characterization through DSC and SEM indicated the drug’s transformation from crystalline to amorphous form, improving dissolution. FTIR studies confirmed no interaction between the drug and carriers. In vitro dissolution tests revealed that β-cyclodextrin (1:9) formulations significantly increased the dissolution rate compared to pure Irbesartan and other carriers. Thus, using β-cyclodextrin in solid dispersions effectively enhances Irbesartan’s solubility and therapeutic potential in treating hypertension.